EUCTR2011-000582-13-GB进行中（未招募）1 期
A 16-week, randomized, placebo-controlled, double blind, and parallel group trial to assess the anti-inflammatory effects of Roflumilast in chronic obstructive pulmonary disease The ROBERT study (Roflumilast Biopsy European Research Trial)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 158
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subjects meeting the following criteria will be considered for inclusion in the run-in period:
- •1) Written informed consent obtained according to local regulations before any trial-related activities. A trial-related activity is any procedure that would not have been performed during the routine management of the Subject.
- •2) History of COPD (according to GOLD 2009) for at least 12 months prior to baseline visit V0 associated with chronic productive cough for at least three months in each of the two years prior to baseline visit V0 (with other causes of productive cough ex-cluded)
- •3) Outpatients 40-80 years of age
- •4) Post-bronchodilator 30% =FEV1 =80% predicted
- •5) Post-bronchodilator FEV1/FVC ratio =70%
- •6) Current or former smokers with smoking history =20 pack years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 130
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1) Clinical instability, defined as experiencing a COPD exacerbation six months prior to V0, as indicated by treatment with a systemically administered glucocorticosteroid and/or antibiotics and/or hospitalization
- •2) An upper/lower respiratory tract infection e.g. common cold, sinus symptoms, pneu-monia, which has not resolved four weeks prior to V0
- •3) Diagnosis of asthma and/or other relevant lung disease (e.g. history of primary or clinically significant bronchiectases, cystic fibrosis, bronchiolitis, lung resection, lung cancer, interstitial lung disease [e.g. fibrosis, silicosis, sarcoidosis], active tuberculo-sis) or previous episodes of pneumothorax
- •4) Known alpha-1-antitrypsin deficiency
- •Criteria within ethical considerations in terms of general health:
- •5) Duration of oxygen therapy =12 h/day
- •6) History of intubation for COPD or a respiratory failure of any cause in the past year
- •7) Hypoxemia defined as oxyhemoglobin concentration <88% when breathing room air measured by pulse oximetry
- •8) Formal contraindications to sputum collection or impossibility to obtain a sample of sputum valid for analysis
- •9) Clinically relevant abnormal laboratory values suggesting an undiagnosed disease requiring further clinical evaluation (as assessed by the Investigator)
- •10) Suspicion or diagnosis of a bleeding disorders irrespective of its pathophysiological mechanism: Thrombocytopenia (platelets <50000/mL) and platelet dysfunction (e.g. uraemia), thrombotic or coagulation disorders and bleeding due to abnormal blood vessels (e.g. purpura simplex)
- •11) Severe psychiatric or neurological disorders
- •12)History of depression associated with suicidal ideation or behaviour
- •13) Hemodynamic instability (e.g. bradycardia with resting heart rate <60 beats per min, tachycardia with resting heart rate =120 beats per min and/or a systolic blood pres-sure <100 or >180 mmHg)
- •14)History of increased intracranial pressure, superior vena cava obstruction, pulmonary hypertension, aneurysms and arteriovenous malformations within the lungs
- •15)Congestive heart failure severity grade IV according to New York Heart Association Functional Classification (NYHA)
- •16)Haemodynamically significant cardiac arrhythmias or heart valve deformations
- •17)History of angina pectoris (Class =II Canadian Cardiovascular Society Functional Classification of Angina Pectoris Scale) or a myocardial infarction within last 12 months, unless corrected with Percutaneous Transluminal Coronary Angioplasty (PTCA) or Coronary Artery Bypass Surgery (CABG) =3 months prior to V0 and as-ymptomatic since then
- •18) X-ray Computed Tomography (CT) or X-ray findings indicating a pulmonary disease other than COPD (e.g. tuberculosis, clinically significant bronchiectases, tumours). CT or X-ray results within 12 months prior to visit V0 are required.
- •19) Immunological diseases or known infection with Human Immunodeficiency Virus (HIV)
- •20) Liver impairment Child-Pugh B/C and/or active viral hepatitis
- •21) Severe acute infectious diseases
- •22) Any diagnosis of a malignant disease (other than basal or squamous cell carcinoma) within five
研究者
相似试验
进行中（未招募）
不适用
The trial investigates the anti-inflammatory effects of 500 µg roflumilast tablets once daily in patients with chronic obstructive pulmonary disease (COPD)EUCTR2011-000582-13-PLTakeda Development Centre Europe Ltd.150
进行中（未招募）
1 期
The trial investigates the anti-inflammatory effects of 500 µg roflumilast tablets once daily in patients with chronic obstructive pulmonary disease (COPD)severe chronic obstructive pulmonary disease (COPD)MedDRA version: 17.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2011-000582-13-DETakeda Development Centre Europe Ltd.150
进行中（未招募）
不适用
The trial investigates the anti-inflammatory effects of 500 µg roflumilast tablets once daily in patients with chronic obstructive pulmonary disease (COPD)severe chronic obstructive pulmonary disease (COPD)MedDRA version: 18.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2011-000582-13-DKTakeda Development Centre Europe Ltd.150
进行中（未招募）
不适用
The trial investigates the anti-inflammatory effects of 500 µg roflumilast tablets once daily in patients with chronic obstructive pulmonary disease (COPD)severe chronic obstructive pulmonary disease (COPD)MedDRA version: 17.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2011-000582-13-SETakeda Development Centre Europe Ltd.150
招募中
不适用
A 16-week, randomized, double-blinded, placebo-controlled study of HT077 and HT048 to evaluate efficacy and safety on health subjects with overweightKCT0004271EUMED120